Combining Complementary Mechanisms of Action (MOA's)

  • TXL directly inhibits HBV replication
  • CRV431 blocks HBV from entering liver cells; interrupts viral life cycle at multiple points through interactions with host molecules

Curing Hepatitis B with Combination Therapy

Curing hepatitis B is at the forefront of ContraVir’s research and business strategy. Similar to other major viral infections like hepatitis C and HIV, experts now believe that combining different drugs that can work together against HBV into a single regimen will be the most likely way to achieve a cure. A cure for hepatitis B may be through full eradication of the virus from the body (similar to hepatitis C) or what is known as a “functional cure” whereby viral levels are minimal and any negative effects are eliminated with continuous therapy (similar to HIV).

The mechanisms of action of ContraVir’s two HBV drugs TXL and CRV431 are distinct and complementary to each other, inhibiting viral replication at multiple different points in the HBV life cycle. Both drugs are next-generation derivatives of proven antiviral compounds and have demonstrated potentially best-in-class potency in vitro. Higher potency helps minimize the dose required for antiviral activity, as well as potentially reduce any side effects. It also maximizes the opportunity to use TXL and CRV431 in combination with each other and additional molecules to create a uniquely powerful and potentially curative anti-HBV regimen. ContraVir is focused on advancing its HBV portfolio and working towards a functional cure for hepatitis B.

Hepatitis B Virus (HBV)